LLY

1,072.27

+1.4%↑

JNJ

206

-1.09%↓

ABBV

227.14

+1.9%↑

UNH

327.43

-0.31%↓

AZN

91.35

+0.79%↑

LLY

1,072.27

+1.4%↑

JNJ

206

-1.09%↓

ABBV

227.14

+1.9%↑

UNH

327.43

-0.31%↓

AZN

91.35

+0.79%↑

LLY

1,072.27

+1.4%↑

JNJ

206

-1.09%↓

ABBV

227.14

+1.9%↑

UNH

327.43

-0.31%↓

AZN

91.35

+0.79%↑

LLY

1,072.27

+1.4%↑

JNJ

206

-1.09%↓

ABBV

227.14

+1.9%↑

UNH

327.43

-0.31%↓

AZN

91.35

+0.79%↑

LLY

1,072.27

+1.4%↑

JNJ

206

-1.09%↓

ABBV

227.14

+1.9%↑

UNH

327.43

-0.31%↓

AZN

91.35

+0.79%↑

Strona główna・Stock List・Madrigal Pharmaceuticals Inc

Madrigal Pharmaceuticals Inc

Closed

SectorHealthcare

590.67 8.85

Buy Sell

Overview

Share price change

24h

Current

Min

579.29

Max

592.33

Key metrics
By Trading Economics
Income	-72M -114M
Sales	74M 287M
EPS	-4.956
Profit margin	-39.75
Employees	528
EBITDA	-75M -114M

Recommendations
By TipRanks
Recommendations	Strong Buy
12 Months Forecast	+3.97% upside

Market Stats
By TradingEconomics
Market Cap	3.5B 13B
Previous open	581.82
Previous close	590.67

News Sentiment

By Acuity

34%

66%

78 / 374 Ranking in Healthcare

Technical Score

By Trading Central

Confidence

Very Strong Bearish Evidence

263.2 / 277.1 Support & Resistance

Madrigal Pharmaceuticals Inc Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

19 gru 2025, 17:29 UTC

Acquisitions, Mergers, Takeovers

Union Pacific, Norfolk Southern File for Merger Approval From Surface Transportation Board -- 2nd Update

19 gru 2025, 16:47 UTC

Major Market Movers

Galectin Shares Fall After FDA Raises Issues With Belapectin Program

19 gru 2025, 16:10 UTC

Acquisitions, Mergers, Takeovers

Union Pacific, Norfolk Southern File for Merger Approval From Surface Transportation Board -- Update

21 gru 2025, 23:51 UTC

Market Talk

Oil Rises Amid Growing U.S.-Venezuela Tensions -- Market Talk

21 gru 2025, 23:45 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

21 gru 2025, 23:45 UTC

Market Talk

Nikkei May Rise as Yen Weakens -- Market Talk

21 gru 2025, 23:35 UTC

Market Talk

Gold Edges Higher Amid Geopolitical Tensions -- Market Talk

19 gru 2025, 22:33 UTC

Earnings

Volkswagen Halts Imports of Its Electric Bus to U.S. Next Year -- WSJ

19 gru 2025, 22:19 UTC

Earnings

FedEx Earnings Were Strong. Cost Cuts and Shipment Volume Helped. -- Barrons.com

19 gru 2025, 21:48 UTC

Acquisitions, Mergers, Takeovers

Trump Media Is Making a Big Pivot. Kodak Tried That, Too. -- Barrons.com

19 gru 2025, 21:44 UTC

Earnings

These Stocks Moved the Most Today: Oracle, Nike, Micron, DJT, Carnival, BioMarin, CoreWeave, Lamb Weston, and More -- Barrons.com

19 gru 2025, 21:38 UTC

Earnings

Get Ready for New Chip Shortages. Micron's Success All But Guarantees It. -- Barrons.com

19 gru 2025, 21:00 UTC

Market Talk

BEA's Trade-Data Catchup Will Continue Into January -- Market Talk

19 gru 2025, 20:23 UTC

Market Talk

Oil Futures End Down Week on Up Note -- Market Talk

19 gru 2025, 20:14 UTC

Market Talk

U.S. Natural Gas Futures Post Daily Gain, Weekly Loss -- Market Talk

19 gru 2025, 18:38 UTC

Market Talk

U.S. Oil Rig Count Falls By 8 to 406 -- Market Talk

19 gru 2025, 18:00 UTC

Market Talk

Earnings

Nike's Margin Outlook Shows Quarter-to-Quarter Improvement -- Market Talk

19 gru 2025, 17:41 UTC

Earnings

These Stocks Are Moving the Most Today: Oracle, Nike, Micron, DJT, Carnival, BioMarin, CoreWeave, Lamb Weston, and More -- Barrons.com

19 gru 2025, 17:24 UTC

Market Talk

Earnings

Nike's North America Business is Bright Spot in Turnaround -- Market Talk

19 gru 2025, 17:20 UTC

Market Talk

Acquisitions, Mergers, Takeovers

Tech, Media & Telecom Roundup: Market Talk

19 gru 2025, 17:20 UTC

Market Talk

Financial Services Roundup: Market Talk

19 gru 2025, 16:29 UTC

Earnings

These Stocks Are Moving the Most Today: Oracle, Nike, FedEx, Micron, DJT, Carnival, BioMarin, Lamb Weston, Winnebago, and More -- Barrons.com

19 gru 2025, 16:20 UTC

Acquisitions, Mergers, Takeovers

CPKC: Anticipates Submitting Comments to Surface Transportation Board in Accordance With Procedural Schedule

19 gru 2025, 16:19 UTC

Acquisitions, Mergers, Takeovers

CPKC: Approval of Union Pacific-Norfolk Southern Merger Isn't Inevitable

19 gru 2025, 16:18 UTC

Acquisitions, Mergers, Takeovers

CPKC: Will Be Thoroughly Reviewing Union Pacific-Norfolk Southern Merger Application Over Coming Days

19 gru 2025, 16:16 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

19 gru 2025, 16:16 UTC

Market Talk

U.K. Public Borrowing Data Shows Slow Progress in Reducing Fiscal Deficit -- Market Talk

19 gru 2025, 16:05 UTC

Acquisitions, Mergers, Takeovers

Trump Media Is Making a Big Pivot. Kodak Tried That, Too. -- Barrons.com

19 gru 2025, 16:04 UTC

Acquisitions, Mergers, Takeovers

Trump Media Is Making a Big Pivot. Kodak Tried That, Too. -- Barrons.com

19 gru 2025, 15:37 UTC

Market Talk

U.S. Labor Market Weakness Could Cause Further Fed Rate Cuts -- Market Talk

Peer Comparison

Price change

Madrigal Pharmaceuticals Inc Forecast

Price Target

By TipRanks

3.97% upside

12 Months Forecast

Average 614.5 USD 3.97%

High 900 USD

Low 523 USD

Based on 12 Wall Street analysts offering 12 month price targets forMadrigal Pharmaceuticals Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

12 ratings

Buy

Hold

Sell

Based on 12 analysts giving stock ratings to Madrigal Pharmaceuticals Inc - Dist in the past 3 months.

Technical Score

By Trading Central

263.2 / 277.1Support & Resistance

Bearish events outweigh bullish events.

Recent bearish events outweigh bullish events.

The bullish and bearish events are balanced.

Sentiment

By Acuity

78 / 374 Ranking in Healthcare

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About Madrigal Pharmaceuticals Inc

Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of non-alcoholic steatohepatitis (NASH) in the United States. Its lead product candidate is resmetirom, a liver-directed thyroid hormone receptor beta agonist, which is in Phase 3 clinical trials for treating NASH. The company is headquartered in West Conshohocken, Pennsylvania.